​
​

Dianthus Therapeutics Ownership | Who Owns Dianthus Therapeutics?

OverviewRevenueFinancialsChart

Dianthus Therapeutics Ownership Summary

Dianthus Therapeutics is owned by 47.55% institutional investors, and 52.45% retail investors. Vanguard Instl Ttl Stck Mkt Idx Tr is the top mutual fund, with 2.36% of its assets in Dianthus Therapeutics shares.

MGTA Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockDianthus Therapeutics47.55%-52.45%
SectorHealthcare Stocks 46.98%7.90%45.12%
IndustryBiotech Stocks 44.85%7.67%47.48%

Institutional Shareholders

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 202343-15.69%28,834,243-2.22%472.01%13-45.83%1110.00%
Mar 31, 202351-1.92%29,489,5735.49%482.19%244.35%10-28.57%
Dec 31, 202252-22.39%27,955,148-39.79%470.77%234.55%14-41.67%
Sep 30, 202267-5.63%46,426,8002.18%781.31%22-35.29%2433.33%
Jun 30, 202271-15.48%45,438,307-5.04%771.17%346.25%18-35.71%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Instl Ttl Stck Mkt Idx Tr1.43M2.36%-
Fidelity® Series Small Cap Opps429.68K0.71%-
Fidelity® Stock Selector Small Cap193.10K0.32%-
Fidelity® Extended Market Index190.58K0.31%-
Fidelity® Total Market Index49.50K0.08%-
Fidelity® Series Total Market Index47.84K0.08%-
Fidelity® NASDAQ Composite Index®44.60K0.07%-
Schwab Total Stock Market Index27.37K0.05%-
SSgA U.S. Extended Market Index Class I11.80K0.02%-
SSgA U.S. Total Market Index Strategy3.71K0.01%-10.00

Recent Insider Transactions

DateNameRoleActivityValue
Sep 29, 2023Fairmount Funds Management LLC Buy$336.25K
Sep 26, 2023Fairmount Funds Management LLC Buy$394.50K
Sep 22, 2023Randhawa Simrat Chief Medical OfficerBuy$26.40K
Sep 21, 2023Randhawa Simrat Chief Medical OfficerBuy$26.40K
Sep 19, 2023Fairmount Funds Management LLC Buy$396.00K

Insider Transactions Trends

DateBuySell
2023 Q36-
2023 Q1-2
2022 Q4--
2022 Q3--
2022 Q2--

MGTA Ownership FAQ

Who Owns Dianthus Therapeutics?

Dianthus Therapeutics shareholders are primarily institutional investors at 47.55%, followed by 0% insiders and 0% retail investors. The average institutional ownership in Dianthus Therapeutics's industry, Biotech Stocks , is 44.85%, which Dianthus Therapeutics exceeds.

Does Blackrock own Dianthus Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Dianthus Therapeutics.

Who is the top mutual fund holder of Dianthus Therapeutics shares?

Vanguard Instl Ttl Stck Mkt Idx Tr is the top mutual fund holder of Dianthus Therapeutics shares, with 2.36% of its total shares outstanding invested in 1.43M Dianthus Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools